Video Library

Dr. Luis Raez, MD FACP FCCP, Chief of Hem/Onc and Med. Dir. at Memorial Cancer Institute, and Clinical Associate Prof. of Medicine at FL International University discusses Multiple Immunotherapy Agents.

Dr. Luis Raez, MD FACP FCCP, Chief of Hem/Onc and Med. Dir. at Memorial Cancer Institute, and Clinical Associate Prof. of Medicine at FL International University discusses the Role for Immunotherapy for Patients with Driver Mutations.

Drs. H. Jack West, Matthew Gubens, and Jyoti Patel, gathered post ASCO 2017 to discuss new information regarding lung cancer. In this video, the doctors discuss Continuing Immunotherapy Beyond Progression.

Jack West, MD, President and CEO of GRACE provides updates to our Lung Cancer Video Library. In this recent video, Dr. West discusses PDL1 as a biomarker for first line.

Jack West, MD, President and CEO of GRACE provides updates to our Lung Cancer Video Library. In this recent video, Dr. West discusses PDL1 as a biomarker for second line.

Stephen Liu, MD provides updates to our Lung Cancer Video Library. In this recent video, Dr. Liu discusses Continuing Immunotherapy Beyond Progression-In Which Patients Is This Appropriate

Dr. Jared Weiss, Vice President of GRACE and Associate Professor at UNC-Chapel Hill in Clinical Research, and the Thoracic Oncology Program at UNC Lineberger, discusses if there is a role for PD-L1 testing after first line treatment.

GRACE sat down with Dr. Marco Ruiz to discuss information regarding all diffuse large B-cell lymphoma (DLBCL) and are they made equally ("¿Todos los linfomas difusos de linfocitos B (DLBCL) están hechos iguales?"). Stay tuned for more on our continuing video series with our Spanish speaking faculty

GRACE sat down with Dr. Marco Ruiz to discuss information regarding the role of surveillance imaging in indolent lymphomas and chronic lymphocytic leukemia (CLL) (¿Cuál es el rol de vigilancia imagenológica en linfomas indolentes y en la leucemia crónica linfocítica?). Stay tuned for more on our

GRACE sat down with Dr. Marco Ruiz to discuss information regarding inhibitory molecules like the programmed cell death protein 1 (PD1) and its ligand (PDL1), and if they are active in lymphoma and in chronic lymphocytic leukemia (¿Están activos moléculas inhibitorias como el de la muerte programada

GRACE sat down with Cesar A. De Las Casas, MD, MPH, to discuss information regarding if there is a best maintenance therapy (¿Existe una terapia de mantenimiento mejor sobre las demás?). Stay tuned for more on our continuing video series with our Spanish speaking faculty on updates in blood cancer

GRACE sat down with Cesar A. De Las Casas, MD, MPH, to discuss information regarding whether all patients should receive an autologous transplant (¿Todos deberían de recibir un trasplante autólogo?). Stay tuned for more on our continuing video series with our Spanish speaking faculty on updates in

GRACE sat down with Cesar A. De Las Casas, MD, MPH, to discuss information regarding the new antibodies for multiple myeloma (MM) therapy (¿Cuáles son los anticuerpos nuevos para la terapia del mieloma múltiple (MM)?). Stay tuned for more on our continuing video series with our Spanish speaking

GRACE sat down with Cesar A. De Las Casas, MD, MPH, to discuss information regarding if there a preferred induction therapy (¿¿Hay alguna terapia de inducción preferida?). Stay tuned for more on our continuing video series with our Spanish speaking faculty on updates in blood cancer treatments, and

Dr. Nathan Pennell, Cleveland Clinic, evaluates chemotherapy sensitivity assays, describing the difficulties inherent in predicting response to chemotherapy agents.